Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Liabilities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Other Non-Current Liabilities for 11 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 23.25% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, down 23.25% year-over-year, with the annual reading at $4.9 million for FY2025, 8.59% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $4.9 million at Aytu Biopharma, down from $20.4 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $20.4 million in Q3 2025, with the low at $371000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $7.8 million, with a median of $6.4 million recorded in 2024.
  • Peak annual rise in Other Non-Current Liabilities hit 167918.18% in 2021, while the deepest fall reached 95.55% in 2021.
  • Over 5 years, Other Non-Current Liabilities stood at $560000.0 in 2021, then surged by 641.96% to $4.2 million in 2022, then surged by 52.68% to $6.3 million in 2023, then rose by 0.66% to $6.4 million in 2024, then decreased by 23.25% to $4.9 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $4.9 million, $20.4 million, and $4.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.